The University of Chicago Header Logo

Connection

George Bakris to Antihypertensive Agents

Back to Details
This is a "connection" page, showing publications George Bakris has written about Antihypertensive Agents.
George Bakris
Connection Strength
42.466
Antihypertensive Agents
  1. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023 Jul 20; 389(3):228-238.
    View in: PubMed
    Score: 0.667
  2. Novel antihypertensive agents for resistant hypertension: what does the future hold? Hypertens Res. 2022 12; 45(12):1918-1928.
    View in: PubMed
    Score: 0.631
  3. How to Manage Hypertension in People With Diabetes. Am J Hypertens. 2020 10 21; 33(10):935-943.
    View in: PubMed
    Score: 0.552
  4. Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254.
    View in: PubMed
    Score: 0.524
  5. Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting. Heart Fail Clin. 2019 Oct; 15(4):455-461.
    View in: PubMed
    Score: 0.506
  6. The Management of Hypertension in 2018: What Should the Targets Be? Curr Hypertens Rep. 2019 04 25; 21(6):41.
    View in: PubMed
    Score: 0.497
  7. Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circ Res. 2019 03 29; 124(7):969-971.
    View in: PubMed
    Score: 0.495
  8. Creatinine Bump Following Antihypertensive Therapy. Hypertension. 2018 12; 72(6):1274-1276.
    View in: PubMed
    Score: 0.484
  9. Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used. Eur Heart J. 2018 10 21; 39(40):3662-3663.
    View in: PubMed
    Score: 0.480
  10. Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension? Hypertension. 2018 10; 72(4):836-838.
    View in: PubMed
    Score: 0.478
  11. Blood Pressure Control and Cardiovascular/Renal Outcomes. Endocrinol Metab Clin North Am. 2018 03; 47(1):175-184.
    View in: PubMed
    Score: 0.459
  12. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018 02 08; 378(6):497-499.
    View in: PubMed
    Score: 0.456
  13. Initial Single-Pill Blood Pressure-Lowering Therapy: Should It Be for Most People? J Am Heart Assoc. 2017 11 18; 6(11).
    View in: PubMed
    Score: 0.450
  14. MY APPROACH to the elderly patient with resistant hypertension. Trends Cardiovasc Med. 2018 01; 28(1):79-80.
    View in: PubMed
    Score: 0.447
  15. Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. Clin Pharmacol Ther. 2017 Sep; 102(3):450-458.
    View in: PubMed
    Score: 0.440
  16. Resistant Hypertension: A Refractory Disease or Refractory Patient. Hypertension. 2017 04; 69(4):582-583.
    View in: PubMed
    Score: 0.431
  17. The Kidney in Hypertension. Med Clin North Am. 2017 Jan; 101(1):207-217.
    View in: PubMed
    Score: 0.424
  18. Current Status of Renal Denervation in Hypertension. Curr Cardiol Rep. 2016 11; 18(11):107.
    View in: PubMed
    Score: 0.419
  19. Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. Am J Kidney Dis. 2016 Nov; 68(5S1):S15-S23.
    View in: PubMed
    Score: 0.419
  20. From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. Lancet. 2016 Jul 30; 388(10043):530-2.
    View in: PubMed
    Score: 0.398
  21. Summary and Conclusions. High Blood Press Cardiovasc Prev. 2015 Jul; 22 Suppl 1:S23.
    View in: PubMed
    Score: 0.382
  22. Update on blood pressure goals in diabetes mellitus. Curr Cardiol Rep. 2015 Jun; 17(6):37.
    View in: PubMed
    Score: 0.380
  23. Hypertension: Impact of blood pressure lowering in type 2 diabetes. Nat Rev Nephrol. 2015 Jun; 11(6):320-1.
    View in: PubMed
    Score: 0.376
  24. Renal denervation for resistant hypertension and beyond. Adv Chronic Kidney Dis. 2015 Mar; 22(2):133-9.
    View in: PubMed
    Score: 0.373
  25. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens. 2015 Apr; 9(4):266-74.
    View in: PubMed
    Score: 0.371
  26. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015 May; 31(5):642-8.
    View in: PubMed
    Score: 0.367
  27. Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated? J Renin Angiotensin Aldosterone Syst. 2014 Mar; 15(1):97-8.
    View in: PubMed
    Score: 0.348
  28. Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches. J Clin Hypertens (Greenwich). 2014 Feb; 16(2):141-8.
    View in: PubMed
    Score: 0.346
  29. Review of blood pressure control rates and outcomes. J Am Soc Hypertens. 2014 Feb; 8(2):127-41.
    View in: PubMed
    Score: 0.342
  30. Chronic kidney disease: optimal blood pressure for kidney disease-lower is not better. Nat Rev Nephrol. 2013 Nov; 9(11):634-5.
    View in: PubMed
    Score: 0.338
  31. Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience. J Hypertens. 2013 Aug; 31(8):1537-8.
    View in: PubMed
    Score: 0.334
  32. Lowering blood pressure limits in patients with type 2 diabetes: is it still warranted? J Diabetes Complications. 2013 Sep-Oct; 27(5):415-6.
    View in: PubMed
    Score: 0.329
  33. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013 Jul 15; 112(2):255-9.
    View in: PubMed
    Score: 0.327
  34. Recognition and management of masked hypertension: a review and novel approach. J Am Soc Hypertens. 2013 May-Jun; 7(3):244-52.
    View in: PubMed
    Score: 0.326
  35. Hypertensive goals in patients with coronary artery disease. Curr Cardiol Rep. 2012 Dec; 14(6):667-72.
    View in: PubMed
    Score: 0.319
  36. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100.
    View in: PubMed
    Score: 0.317
  37. Timing and efficacy of alternative methods of sympathetic blockade. Curr Hypertens Rep. 2012 Oct; 14(5):455-61.
    View in: PubMed
    Score: 0.316
  38. Approaches for targeting blood pressure control in sleep disorders. Curr Opin Nephrol Hypertens. 2012 Sep; 21(5):469-74.
    View in: PubMed
    Score: 0.314
  39. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012 Dec; 125(12):1229.e1-1229.e10.
    View in: PubMed
    Score: 0.314
  40. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012 Mar; 10(2):156-61.
    View in: PubMed
    Score: 0.303
  41. Hypertension in 2011: New insights--from risk factors to treatment implications. Nat Rev Cardiol. 2011 Dec 13; 9(2):75-7.
    View in: PubMed
    Score: 0.299
  42. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage? Curr Opin Nephrol Hypertens. 2011 Sep; 20(5):471-5.
    View in: PubMed
    Score: 0.293
  43. Initial combination antihypertensives: let's ACCELERATE. Lancet. 2011 Jan 22; 377(9762):278-9.
    View in: PubMed
    Score: 0.280
  44. Treatment and control of high blood pressure in adults. Cardiol Clin. 2010 Nov; 28(4):609-22.
    View in: PubMed
    Score: 0.276
  45. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010 Nov-Dec; 4(6):302-10.
    View in: PubMed
    Score: 0.276
  46. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):678-86.
    View in: PubMed
    Score: 0.270
  47. More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors. J Hypertens. 2010 Jul; 28(7):1382-3.
    View in: PubMed
    Score: 0.270
  48. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81.
    View in: PubMed
    Score: 0.263
  49. Hypertension goals in advanced-stage kidney disease. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S92-4.
    View in: PubMed
    Score: 0.259
  50. The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep. 2009 Nov; 11(6):436-42.
    View in: PubMed
    Score: 0.258
  51. Hypertension and its management in the elderly. Semin Nephrol. 2009 Nov; 29(6):604-9.
    View in: PubMed
    Score: 0.258
  52. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):386-91.
    View in: PubMed
    Score: 0.255
  53. The future of blood pressure control in a population with a growing girth. Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):379-80.
    View in: PubMed
    Score: 0.255
  54. Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes Obes Metab. 2009 Aug; 11(8):757-69.
    View in: PubMed
    Score: 0.251
  55. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol. 2009 May; 53(5):379-87.
    View in: PubMed
    Score: 0.249
  56. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Clin J Am Soc Nephrol. 2009 Mar; 4(3):517-9.
    View in: PubMed
    Score: 0.245
  57. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Clin Exp Nephrol. 2009 Feb; 13(1):96-9.
    View in: PubMed
    Score: 0.245
  58. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25; 52(22):1749-57.
    View in: PubMed
    Score: 0.242
  59. Mechanistic insights into diuretic-induced insulin resistance. Hypertension. 2008 Dec; 52(6):1009-11.
    View in: PubMed
    Score: 0.241
  60. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens. 2008 Sep; 17(5):457-63.
    View in: PubMed
    Score: 0.238
  61. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich). 2008 Sep; 10(9):707-13; discussion 714-5.
    View in: PubMed
    Score: 0.238
  62. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab. 2009 Mar; 11(3):177-87.
    View in: PubMed
    Score: 0.234
  63. Newer combination therapies in the management of hypertension: an update. J Clin Hypertens (Greenwich). 2008 May; 10(5):398-405.
    View in: PubMed
    Score: 0.232
  64. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr; 121(4):332-40.
    View in: PubMed
    Score: 0.231
  65. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Ann Intern Med. 2008 Mar 04; 148(5):400-1.
    View in: PubMed
    Score: 0.230
  66. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich). 2008 Feb; 10(2):146-52.
    View in: PubMed
    Score: 0.228
  67. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008 Jan; 10(1 Suppl 1):27-32.
    View in: PubMed
    Score: 0.227
  68. Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient? Prev Cardiol. 2008; 11(1):42-9.
    View in: PubMed
    Score: 0.227
  69. Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. Pol Arch Med Wewn. 2007 Sep; 117(9):389-90.
    View in: PubMed
    Score: 0.222
  70. ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression? J Clin Hypertens (Greenwich). 2007 Jun; 9(6):413-5.
    View in: PubMed
    Score: 0.218
  71. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007 Jun; 7(3):191-9.
    View in: PubMed
    Score: 0.218
  72. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens. 2007 Jan; 25(1):249-52; author reply 252-3.
    View in: PubMed
    Score: 0.212
  73. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007 Jan; 49(1):12-26.
    View in: PubMed
    Score: 0.212
  74. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9.
    View in: PubMed
    Score: 0.212
  75. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec; 29(12):2592-7.
    View in: PubMed
    Score: 0.211
  76. The continuum of blood pressure risk: when is the best time to intervene? Curr Hypertens Rep. 2006 Oct; 8(5):395-7.
    View in: PubMed
    Score: 0.208
  77. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care. 2006 May; 29(5):1167-9.
    View in: PubMed
    Score: 0.202
  78. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006 May; 8(5):351-6; quiz 357-8.
    View in: PubMed
    Score: 0.202
  79. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):587-95; quiz 596-7.
    View in: PubMed
    Score: 0.194
  80. Is ethnicity a factor in choice of antihypertensive drug? Postgrad Med. 2005 May; 117(5):40.
    View in: PubMed
    Score: 0.189
  81. Preventing hypertensive kidney disease: the critical role of combination therapy. Am J Hypertens. 2005 Apr; 18(4 Pt 2):93S-94S.
    View in: PubMed
    Score: 0.188
  82. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens. 2005 Apr; 18(4 Pt 2):112S-119S.
    View in: PubMed
    Score: 0.188
  83. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
    View in: PubMed
    Score: 0.186
  84. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10; 292(18):2227-36.
    View in: PubMed
    Score: 0.183
  85. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004 Nov; 44(5):637-42.
    View in: PubMed
    Score: 0.181
  86. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):437-42; quiz 443-4.
    View in: PubMed
    Score: 0.179
  87. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
    View in: PubMed
    Score: 0.178
  88. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. Hypertension. 2004 May; 43(5):941-2.
    View in: PubMed
    Score: 0.175
  89. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024 03 05; 331(9):740-749.
    View in: PubMed
    Score: 0.174
  90. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar; 13(2):155-61.
    View in: PubMed
    Score: 0.174
  91. Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade. Eur Heart J. 2024 Jan 07; 45(2):136-138.
    View in: PubMed
    Score: 0.172
  92. What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207.
    View in: PubMed
    Score: 0.172
  93. Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients? Am J Kidney Dis. 2003 Dec; 42(6):1301-4.
    View in: PubMed
    Score: 0.171
  94. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747.
    View in: PubMed
    Score: 0.167
  95. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003 Jul 14; 163(13):1555-65.
    View in: PubMed
    Score: 0.167
  96. Achieving blood pressure goals: is fixed-dose combination therapy the answer? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):2-3.
    View in: PubMed
    Score: 0.166
  97. Who should be treated with combination therapy as initial treatment for hypertension? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):21-8.
    View in: PubMed
    Score: 0.166
  98. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Postgrad Med. 2003 May; 113(5):35-40, 43-4, 50.
    View in: PubMed
    Score: 0.164
  99. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003 May-Jun; 5(3):202-9.
    View in: PubMed
    Score: 0.164
  100. Novel Therapies on the Horizon of Hypertension Management. Am J Hypertens. 2023 02 13; 36(2):73-81.
    View in: PubMed
    Score: 0.162
  101. Newer alternatives for resistant hypertension: Beyond 2022 paradigms. Hellenic J Cardiol. 2023 Mar-Apr; 70:75-77.
    View in: PubMed
    Score: 0.162
  102. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Curr Opin Nephrol Hypertens. 2003 Jan; 12(1):79-84.
    View in: PubMed
    Score: 0.161
  103. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 12 03; 400(10367):1927-1937.
    View in: PubMed
    Score: 0.159
  104. Hypertension and diabetes: family physicians' pivotal role. Am Fam Physician. 2002 Oct 01; 66(7):1151-2.
    View in: PubMed
    Score: 0.158
  105. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens. 2022 10 01; 40(10):1847-1858.
    View in: PubMed
    Score: 0.156
  106. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31.
    View in: PubMed
    Score: 0.155
  107. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad Med. 2023 Apr; 135(3):224-233.
    View in: PubMed
    Score: 0.153
  108. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37-47.
    View in: PubMed
    Score: 0.150
  109. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4(1):52-7.
    View in: PubMed
    Score: 0.150
  110. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens. 2002 Jan; 15(1 Pt 1):53-7.
    View in: PubMed
    Score: 0.150
  111. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001 Dec 10-24; 161(22):2661-7.
    View in: PubMed
    Score: 0.149
  112. An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. Expert Opin Investig Drugs. 2021 Oct; 30(10):1017-1023.
    View in: PubMed
    Score: 0.148
  113. Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints: Tailoring Therapy. Cardiol Clin. 2021 Aug; 39(3):377-387.
    View in: PubMed
    Score: 0.146
  114. Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications. Am J Med. 2021 10; 134(10):1195-1198.
    View in: PubMed
    Score: 0.145
  115. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich). 2001 Jan-Feb; 3(1):16-21.
    View in: PubMed
    Score: 0.140
  116. Evolution of drugs that preserve renal function. J Clin Pharmacol. 2000 Sep; 40(9):978-89.
    View in: PubMed
    Score: 0.137
  117. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep; 36(3):646-61.
    View in: PubMed
    Score: 0.137
  118. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther. 2000 Jun; 14(3):295-301.
    View in: PubMed
    Score: 0.134
  119. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000 Mar 30; 342(13):969-70.
    View in: PubMed
    Score: 0.133
  120. Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance. Hypertension. 2020 04; 75(4):943-944.
    View in: PubMed
    Score: 0.132
  121. Hypertension in patients with diabetes. Overcoming barriers to effective control. Postgrad Med. 2000 Mar; 107(3):29-32, 35-6, 38.
    View in: PubMed
    Score: 0.132
  122. Hypertension in patients with diabetes. Why is aggressive treatment essential? Postgrad Med. 2000 Feb; 107(2):53-6, 61-4.
    View in: PubMed
    Score: 0.131
  123. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open. 2018 12 19; 8(12):e021038.
    View in: PubMed
    Score: 0.121
  124. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90.
    View in: PubMed
    Score: 0.120
  125. Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. J Am Coll Cardiol. 2018 09 11; 72(11):1224-1226.
    View in: PubMed
    Score: 0.119
  126. The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. J Hum Hypertens. 1998 Sep; 12(9):653-5.
    View in: PubMed
    Score: 0.119
  127. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. Am J Cardiol. 2018 11 01; 122(9):1496-1505.
    View in: PubMed
    Score: 0.118
  128. Angiotensin II receptor blockers in hypertension and renal disease. Hosp Pract (1995). 1998 Apr 15; 33(4):19-22.
    View in: PubMed
    Score: 0.116
  129. Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction. Diabetes Res Clin Pract. 1998 Apr; 39 Suppl:S35-42.
    View in: PubMed
    Score: 0.116
  130. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733.
    View in: PubMed
    Score: 0.116
  131. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018 04; 36(4):947-956.
    View in: PubMed
    Score: 0.116
  132. Hypertension. Nat Rev Dis Primers. 2018 03 22; 4:18014.
    View in: PubMed
    Score: 0.115
  133. Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. J Clin Hypertens (Greenwich). 2018 04; 20(4):625-626.
    View in: PubMed
    Score: 0.115
  134. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
    View in: PubMed
    Score: 0.114
  135. Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1309-1318.
    View in: PubMed
    Score: 0.112
  136. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens. 1997 Oct; 10(10 Pt 1):1153-8.
    View in: PubMed
    Score: 0.112
  137. Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846.
    View in: PubMed
    Score: 0.111
  138. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84.
    View in: PubMed
    Score: 0.110
  139. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801.
    View in: PubMed
    Score: 0.108
  140. Treatment of renal failure and blood pressure. Curr Opin Nephrol Hypertens. 1997 May; 6(3):237-42.
    View in: PubMed
    Score: 0.108
  141. Renal mortality associated with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1997 Mar-Apr; 11(2):104-11.
    View in: PubMed
    Score: 0.107
  142. Response by Bakris to Letter Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure". Circulation. 2017 02 14; 135(7):e47.
    View in: PubMed
    Score: 0.107
  143. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. Hypertension. 2017 02; 69(2):220-227.
    View in: PubMed
    Score: 0.106
  144. Is the level of arterial pressure reduction important for preservation of renal function. Nephrol Dial Transplant. 1996 Dec; 11(12):2383-4.
    View in: PubMed
    Score: 0.105
  145. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50.
    View in: PubMed
    Score: 0.105
  146. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996 Sep 23; 156(17):1969-78.
    View in: PubMed
    Score: 0.104
  147. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996 Aug 01; 125(3):201-4.
    View in: PubMed
    Score: 0.103
  148. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr; 34(4):788-97.
    View in: PubMed
    Score: 0.101
  149. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
    View in: PubMed
    Score: 0.101
  150. CLINICAL DECISIONS. Blood-Pressure Control. N Engl J Med. 2015 Nov 26; 373(22):2180-2.
    View in: PubMed
    Score: 0.098
  151. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9.
    View in: PubMed
    Score: 0.097
  152. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015 Oct 17; 386(10003):1588-98.
    View in: PubMed
    Score: 0.097
  153. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec; 66(6):1130-7.
    View in: PubMed
    Score: 0.097
  154. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101.
    View in: PubMed
    Score: 0.096
  155. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81.
    View in: PubMed
    Score: 0.092
  156. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994 Jul; 46(1):161-9.
    View in: PubMed
    Score: 0.089
  157. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7.
    View in: PubMed
    Score: 0.088
  158. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension. Curr Hypertens Rep. 2014 Mar; 16(3):419.
    View in: PubMed
    Score: 0.087
  159. Proceedings from Duke resistant hypertension think tank. Am Heart J. 2014 Jun; 167(6):775-88.e1.
    View in: PubMed
    Score: 0.087
  160. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol. 1994; 23 Suppl 1:S34-8.
    View in: PubMed
    Score: 0.086
  161. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):14-26.
    View in: PubMed
    Score: 0.086
  162. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). J Am Soc Hypertens. 2014 Feb; 8(2):103-16.
    View in: PubMed
    Score: 0.085
  163. Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension. 2013 Sep; 62(3):444-9.
    View in: PubMed
    Score: 0.083
  164. Obesity, blood pressure, and cardiovascular outcomes - Authors' reply. Lancet. 2013 Jun 08; 381(9882):1982-3.
    View in: PubMed
    Score: 0.083
  165. Interventional cardiology: Indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013 Aug; 10(8):434-6.
    View in: PubMed
    Score: 0.083
  166. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8.
    View in: PubMed
    Score: 0.083
  167. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol. 1993 May; 33(5):392-9.
    View in: PubMed
    Score: 0.082
  168. Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. EuroIntervention. 2013 May; 9 Suppl R:R136-9.
    View in: PubMed
    Score: 0.082
  169. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993 Apr 26; 153(8):973-80.
    View in: PubMed
    Score: 0.082
  170. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 Jun; 126(6):501-8.
    View in: PubMed
    Score: 0.082
  171. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013 Feb 16; 381(9866):537-45.
    View in: PubMed
    Score: 0.080
  172. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8.
    View in: PubMed
    Score: 0.080
  173. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14.
    View in: PubMed
    Score: 0.080
  174. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 01; 167(5):1677-87.
    View in: PubMed
    Score: 0.079
  175. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012 May; 30(5):874-6.
    View in: PubMed
    Score: 0.077
  176. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012 Mar; 34(3):537-51.
    View in: PubMed
    Score: 0.076
  177. Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. Postgrad Med. 1992 Feb 15; 91(3):87-91, 94-5.
    View in: PubMed
    Score: 0.076
  178. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.075
  179. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Press. 2012 Apr; 21(2):82-7.
    View in: PubMed
    Score: 0.073
  180. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
    View in: PubMed
    Score: 0.072
  181. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20.
    View in: PubMed
    Score: 0.070
  182. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov; 56(5):824-30.
    View in: PubMed
    Score: 0.069
  183. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29.
    View in: PubMed
    Score: 0.068
  184. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010 Nov; 11(16):2675-86.
    View in: PubMed
    Score: 0.068
  185. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 07; 304(1):61-8.
    View in: PubMed
    Score: 0.068
  186. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010 Jul 01; 363(1):98.
    View in: PubMed
    Score: 0.068
  187. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29; 56(1):77-85.
    View in: PubMed
    Score: 0.067
  188. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 05; 102(9):596-604.
    View in: PubMed
    Score: 0.066
  189. The evolution of antihypertensive therapy: an overview of four decades of experience. J Am Coll Cardiol. 1989 Dec; 14(7):1595-608.
    View in: PubMed
    Score: 0.065
  190. Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich). 2009 Nov; 11(11):636-43.
    View in: PubMed
    Score: 0.064
  191. Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it? Pol Arch Med Wewn. 2009 Nov; 119(11):692-3.
    View in: PubMed
    Score: 0.064
  192. The editor's roundtable: prehypertension. Am J Cardiol. 2009 Oct 15; 104(8):1105-15.
    View in: PubMed
    Score: 0.064
  193. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
    View in: PubMed
    Score: 0.064
  194. The kidney, hypertension, and remaining challenges. Med Clin North Am. 2009 May; 93(3):697-715, Table of Contents.
    View in: PubMed
    Score: 0.062
  195. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009 Apr; 27(4):673-9.
    View in: PubMed
    Score: 0.062
  196. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hypertens. 2009 Mar; 27(3):666-9.
    View in: PubMed
    Score: 0.062
  197. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hum Hypertens. 2009 Mar; 23(3):222-5.
    View in: PubMed
    Score: 0.061
  198. Assessing blood pressure control in dialysis patients: finally a step forward. Hypertension. 2009 Mar; 53(3):448-9.
    View in: PubMed
    Score: 0.061
  199. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009 Mar; 22(3):332-8.
    View in: PubMed
    Score: 0.061
  200. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. Heart Fail Clin. 2008 Oct; 4(4):425-38.
    View in: PubMed
    Score: 0.060
  201. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
    View in: PubMed
    Score: 0.058
  202. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):130-9.
    View in: PubMed
    Score: 0.057
  203. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008 Jan-Feb; 17(1):27-36.
    View in: PubMed
    Score: 0.057
  204. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17.
    View in: PubMed
    Score: 0.057
  205. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9.
    View in: PubMed
    Score: 0.056
  206. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007 Jul; 120(7):610-5.
    View in: PubMed
    Score: 0.055
  207. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007 May; 9(5):355-64.
    View in: PubMed
    Score: 0.054
  208. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med. 2007 Jul; 24(7):759-63.
    View in: PubMed
    Score: 0.054
  209. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1):13-9.
    View in: PubMed
    Score: 0.053
  210. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16(2):80-6.
    View in: PubMed
    Score: 0.053
  211. The cardiometabolic syndrome and calcium channel blocker combination drugs. J Cardiometab Syndr. 2007; 2(3):207-12.
    View in: PubMed
    Score: 0.053
  212. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):840-9.
    View in: PubMed
    Score: 0.053
  213. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol. 2006 Oct 02; 98(7A):46L-52L.
    View in: PubMed
    Score: 0.052
  214. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006 Oct 01; 98(7):890-4.
    View in: PubMed
    Score: 0.052
  215. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
    View in: PubMed
    Score: 0.051
  216. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006 Apr; 98(4):618-26.
    View in: PubMed
    Score: 0.050
  217. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006 Jan; 151(1):176-84.
    View in: PubMed
    Score: 0.049
  218. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
    View in: PubMed
    Score: 0.049
  219. Hypertension treatment guidelines: practical implications. Semin Nephrol. 2005 Jul; 25(4):198-209.
    View in: PubMed
    Score: 0.048
  220. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit. 2005 Jun; 10(3):157-63.
    View in: PubMed
    Score: 0.047
  221. George Bakris, MD: researching ways to combat hypertension. Interview by Mike Mitka. JAMA. 2005 Mar 23; 293(12):1439.
    View in: PubMed
    Score: 0.047
  222. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92.
    View in: PubMed
    Score: 0.046
  223. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004 Sep; 17(9):793-801.
    View in: PubMed
    Score: 0.045
  224. Hypertension control rates: time for translation of guidelines into clinical practice. Am J Med. 2004 Jul 01; 117(1):62-4.
    View in: PubMed
    Score: 0.045
  225. Management of hypertension in the cardiometabolic syndrome and diabetes. Curr Diab Rep. 2004 Jun; 4(3):199-205.
    View in: PubMed
    Score: 0.044
  226. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004 Mar 08; 116 Suppl 5A:30S-38S.
    View in: PubMed
    Score: 0.044
  227. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7.
    View in: PubMed
    Score: 0.043
  228. Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004; 22(1):130-5.
    View in: PubMed
    Score: 0.043
  229. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
    View in: PubMed
    Score: 0.043
  230. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
    View in: PubMed
    Score: 0.042
  231. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
    View in: PubMed
    Score: 0.040
  232. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 Nov; 20(11):2257-67.
    View in: PubMed
    Score: 0.040
  233. Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. Postgrad Med. 2002 Oct; 112(4):73-4, 77-80, 83-4.
    View in: PubMed
    Score: 0.039
  234. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 10 22; 400(10361):1405-1416.
    View in: PubMed
    Score: 0.039
  235. Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61.
    View in: PubMed
    Score: 0.039
  236. Roundtable discussion: problems in the management of hypertension. J Clin Hypertens (Greenwich). 2002 May-Jun; 4(3):207-13.
    View in: PubMed
    Score: 0.038
  237. Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 02 14; 15(3):321-332.
    View in: PubMed
    Score: 0.038
  238. Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. J Am Heart Assoc. 2021 11 16; 10(22):e022479.
    View in: PubMed
    Score: 0.037
  239. Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021 09; 98(3):416-426.
    View in: PubMed
    Score: 0.036
  240. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28.
    View in: PubMed
    Score: 0.036
  241. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539.
    View in: PubMed
    Score: 0.036
  242. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens (Greenwich). 2001 Mar-Apr; 3(2):99-102.
    View in: PubMed
    Score: 0.035
  243. Treatment of stage I hypertension and development of renal dysfunction. J Hum Hypertens. 2001 Feb; 15(2):81-4.
    View in: PubMed
    Score: 0.035
  244. The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. J Clin Pharmacol. 2000 Aug; 40(8):815-25.
    View in: PubMed
    Score: 0.034
  245. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000 Feb 28; 160(4):481-90.
    View in: PubMed
    Score: 0.033
  246. Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines? - An Asian Perspective. Circ J. 2019 02 25; 83(3):504-510.
    View in: PubMed
    Score: 0.030
  247. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998 Oct; 11(10):158S-162S.
    View in: PubMed
    Score: 0.030
  248. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
    View in: PubMed
    Score: 0.029
  249. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 03; 319(13):1319-1320.
    View in: PubMed
    Score: 0.029
  250. Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications. 1997 Nov-Dec; 11(6):352-7.
    View in: PubMed
    Score: 0.028
  251. Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701.
    View in: PubMed
    Score: 0.027
  252. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843.
    View in: PubMed
    Score: 0.027
  253. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017 02; 11(2):81-91.
    View in: PubMed
    Score: 0.026
  254. Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens. 1996 Dec; 9(12 Pt 2):200S-206S.
    View in: PubMed
    Score: 0.026
  255. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med. 1996 Sep 30; 101(3A):33S-46S.
    View in: PubMed
    Score: 0.026
  256. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779.
    View in: PubMed
    Score: 0.024
  257. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995 Jan; 35(1):73-80.
    View in: PubMed
    Score: 0.023
  258. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83.
    View in: PubMed
    Score: 0.023
  259. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43.
    View in: PubMed
    Score: 0.022
  260. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014 Feb; 32(2):415-22.
    View in: PubMed
    Score: 0.022
  261. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014 Jan; 32(1):3-15.
    View in: PubMed
    Score: 0.022
  262. Severe hypertension in a young patient. Hosp Pract (Off Ed). 1993 Oct 15; 28(10):57-64.
    View in: PubMed
    Score: 0.021
  263. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1135-44.
    View in: PubMed
    Score: 0.021
  264. Diabetic nephropathy. What you need to know to preserve kidney function. Postgrad Med. 1993 Apr; 93(5):89-90, 93-5, 99-100.
    View in: PubMed
    Score: 0.020
  265. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am J Hypertens. 1993 Apr; 6(4):140S-147S.
    View in: PubMed
    Score: 0.020
  266. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8.
    View in: PubMed
    Score: 0.020
  267. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):467-72.
    View in: PubMed
    Score: 0.018
  268. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9.
    View in: PubMed
    Score: 0.017
  269. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010 Nov; 56(5):780-800.
    View in: PubMed
    Score: 0.017
  270. Predictors of hypertension control in a diverse general cardiology practice. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):570-7.
    View in: PubMed
    Score: 0.017
  271. Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):22-31.
    View in: PubMed
    Score: 0.016
  272. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):42-50.
    View in: PubMed
    Score: 0.016
  273. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04; 359(23):2417-28.
    View in: PubMed
    Score: 0.015
  274. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92.
    View in: PubMed
    Score: 0.014
  275. The editor's roundtable: revisiting the role of beta blockers in hypertension. Am J Cardiol. 2007 Jul 15; 100(2):253-67.
    View in: PubMed
    Score: 0.014
  276. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich). 2006 Apr; 8(4):241-50; quiz 251-2.
    View in: PubMed
    Score: 0.013
  277. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22.
    View in: PubMed
    Score: 0.011
  278. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6):1206-52.
    View in: PubMed
    Score: 0.011
  279. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9.
    View in: PubMed
    Score: 0.011
  280. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72.
    View in: PubMed
    Score: 0.010
  281. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21; 289(19):2560-72.
    View in: PubMed
    Score: 0.010
  282. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003 Mar 10; 163(5):525-41.
    View in: PubMed
    Score: 0.010
  283. Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained. Postgrad Med. 2002 Oct; 112(4):51-2, 55, 59-62 passim.
    View in: PubMed
    Score: 0.010
  284. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000 Apr; 57(4):1651-61.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.